MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 540266 | Name: Levocetirizine dihydrochloride
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Levocetirizine dihydrochloride is a L-isomer of cetirizine and histamine H1 receptor antagonist. It incrases levels of CD4+ CD25+ T cells and decreases levels of eosinophils, decreasing allergy symptoms.

Chemical Structure

Levocetirizine dihydrochloride
CAS#130018-87-0 (2HCl)

Theoretical Analysis

MedKoo Cat#: 540266

Name: Levocetirizine dihydrochloride

CAS#: 130018-87-0 (2HCl)

Chemical Formula: C21H27Cl3N2O3

Exact Mass: 460.1087

Molecular Weight: 461.81

Elemental Analysis: C, 54.62; H, 5.89; Cl, 23.03; N, 6.07; O, 10.39

Price and Availability

Size Price Availability Quantity
1g USD 150.00 2 Weeks
5g USD 350.00 2 Weeks
10g USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
130018-77-8 (free acid) 130018-87-0 (2HCl)
Synonym
(-)-Cetirizine; UCB 28556; UCB28556; UCB-28556; Xusal; Xyzal; Levocetirizine dihydrochloride
IUPAC/Chemical Name
(R)-2-(2-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride
InChi Key
PGLIUCLTXOYQMV-GHVWMZMZSA-N
InChi Code
InChI=1S/C21H25ClN2O3.2ClH/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26;;/h1-9,21H,10-16H2,(H,25,26);2*1H/t21-;;/m1../s1
SMILES Code
O=C(O)COCCN1CCN([C@@H](C2=CC=C(Cl)C=C2)C3=CC=CC=C3)CC1.[H]Cl.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Levocetirizine dihydrochloride ((R)-Cetirizine dihydrochloride) is a third-generation peripheral H1-receptor antagonist.
In vitro activity:
The addition of levocetirizine to eosinophil cultures caused a dose-dependent decrease in the ability of cells to produce RANTES and eotaxin in response to antigen stimulation, and the minimum concentration that caused a significant decrease was 0.05 μM. Reference: In Vivo. 2014 Jul-Aug;28(4):657-66. https://pubmed.ncbi.nlm.nih.gov/24982238/
In vivo activity:
Levocetirizine attenuated lung edema and mitigated the increases in BALF protein levels, LDH activity, and lung leukocyte recruitment in LPS-challenged rats. Additionally, TNF-α protein levels in BALF and lung tissue were diminished by levocetirizine administration. Levocetirizine also exhibited a potent antioxidant activity as indicated by a decrease in lung tissue levels of malondialdehyde and an enhancement of superoxide dismutase activity. Reference: Biomed Res Int. 2018 Aug 13;2018:7019759. https://pubmed.ncbi.nlm.nih.gov/30186866/
Solvent mg/mL mM comments
Solubility
DMF 3.0 6.50
DMSO 68.0 147.25
Ethanol 7.0 15.16
PBS (pH 7.2) 10.0 21.65
Water 96.0 207.88
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 461.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Kanei A, Asano K, Kanai K, Furuta A, Sasaki K, Suzaki H. Inhibitory action of levocetirizine on the production of eosinophil chemoattractants RANTES and eotaxin in vitro and in vivo. In Vivo. 2014 Jul-Aug;28(4):657-66. PMID: 24982238. 2. Komatsuzaki T, Suzaki I, Hirano K, Kanai K, Asano K, Suzaki H. Suppression of osteopontin functions by levocetirizine, a histamine H1 receptor antagonist, in vitro. Biomed Res Int. 2013;2013:735835. doi: 10.1155/2013/735835. Epub 2013 Dec 30. PMID: 24490170; PMCID: PMC3893813. 3. Fahmi ANA, Shehatou GSG, Salem HA. Levocetirizine Pretreatment Mitigates Lipopolysaccharide-Induced Lung Inflammation in Rats. Biomed Res Int. 2018 Aug 13;2018:7019759. doi: 10.1155/2018/7019759. PMID: 30186866; PMCID: PMC6110004. 4. Nakasone T, Wakuda H, Sugimoto Y, Kamei C. Effects of ICI204,448, naloxone methiodide and levocetirizine on the scratching behavior induced by a κ-opioid antagonist, nor-BNI, in ICR mice. Immunopharmacol Immunotoxicol. 2017 Oct;39(5):292-295. doi: 10.1080/08923973.2017.1354879. Epub 2017 Jul 26. PMID: 28745076.
In vitro protocol:
1. Kanei A, Asano K, Kanai K, Furuta A, Sasaki K, Suzaki H. Inhibitory action of levocetirizine on the production of eosinophil chemoattractants RANTES and eotaxin in vitro and in vivo. In Vivo. 2014 Jul-Aug;28(4):657-66. PMID: 24982238. 2. Komatsuzaki T, Suzaki I, Hirano K, Kanai K, Asano K, Suzaki H. Suppression of osteopontin functions by levocetirizine, a histamine H1 receptor antagonist, in vitro. Biomed Res Int. 2013;2013:735835. doi: 10.1155/2013/735835. Epub 2013 Dec 30. PMID: 24490170; PMCID: PMC3893813.
In vivo protocol:
1. Fahmi ANA, Shehatou GSG, Salem HA. Levocetirizine Pretreatment Mitigates Lipopolysaccharide-Induced Lung Inflammation in Rats. Biomed Res Int. 2018 Aug 13;2018:7019759. doi: 10.1155/2018/7019759. PMID: 30186866; PMCID: PMC6110004. 2. Nakasone T, Wakuda H, Sugimoto Y, Kamei C. Effects of ICI204,448, naloxone methiodide and levocetirizine on the scratching behavior induced by a κ-opioid antagonist, nor-BNI, in ICR mice. Immunopharmacol Immunotoxicol. 2017 Oct;39(5):292-295. doi: 10.1080/08923973.2017.1354879. Epub 2017 Jul 26. PMID: 28745076.
1: Johnson M, Kwatra G, Badyal DK, Thomas EA. Levocetirizine and rupatadine in chronic idiopathic urticaria. Int J Dermatol. 2015 Oct;54(10):1199-204. doi: 10.1111/ijd.12733. Epub 2014 Dec 17. PubMed PMID: 25521304. 2: Kim CH, Kim JK, Kim HJ, Cho JH, Kim JS, Kim YD, Lee HM, Kim SW, Cho KS, Lee SH, Rhee CS, Dhong HJ, Rha KS, Yoon JH. Comparison of intranasal ciclesonide, oral levocetirizine, and combination treatment for allergic rhinitis. Allergy Asthma Immunol Res. 2015 Mar;7(2):158-66. doi: 10.4168/aair.2015.7.2.158. Epub 2014 Dec 18. PubMed PMID: 25729623; PubMed Central PMCID: PMC4341337. 3: Bulca S, Bayramgürler D, Odyakmaz Demirsoy E, Yavuz M, Sikar Aktürk A, Bilen N, Kıran R. Comparison of effects of 5 and 10 mg oral desloratadine and levocetirizine on histamine-induced wheal and flare response in healthy volunteers. J Dermatolog Treat. 2013 Dec;24(6):473-6. doi: 10.3109/09546634.2013.777152. Epub 2013 May 6. PubMed PMID: 23441762. 4: Hiraoka K, Tashiro M, Grobosch T, Maurer M, Oda K, Toyohara J, Ishii K, Ishiwata K, Yanai K. Brain histamine H1 receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine. Expert Opin Drug Saf. 2015 Feb;14(2):199-206. doi: 10.1517/14740338.2015.989831. Epub 2014 Dec 3. PubMed PMID: 25466429. 5: Mösges R, König V, Köberlein J. The effectiveness of levocetirizine in comparison with loratadine in treatment of allergic rhinitis--a meta-analysis. Allergol Int. 2011 Dec;60(4):541-6. doi: 10.2332/allergolint.10-OA-0300. Epub 2011 Sep 25. PubMed PMID: 21918368. 6: Ferrer M. Pharmacokinetic evaluation of levocetirizine. Expert Opin Drug Metab Toxicol. 2011 Aug;7(8):1035-47. doi: 10.1517/17425255.2011.590131. Epub 2011 Jun 4. Review. PubMed PMID: 21639816. 7: Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, Church DS, Dimitrov V, Church MK. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010 Mar;125(3):676-82. doi: 10.1016/j.jaci.2009.11.047. PubMed PMID: 20226302. 8: Goindi S, Kumar G, Kaur A. Novel flexible vesicles based topical formulation of levocetirizine: in vivo evaluation using oxazolone-induced atopic dermatitis in murine model. J Liposome Res. 2014 Sep;24(3):249-57. doi: 10.3109/08982104.2014.899365. Epub 2014 Mar 19. PubMed PMID: 24646413. 9: Kanei A, Asano K, Kanai K, Furuta A, Sasaki K, Suzaki H. Inhibitory action of levocetirizine on the production of eosinophil chemoattractants RANTES and eotaxin in vitro and in vivo. In Vivo. 2014 Jul-Aug;28(4):657-66. PubMed PMID: 24982238. 10: Ali OI, Ismail NS, Elgohary RM. Validated derivative and ratio derivative spectrophotometric methods for the simultaneous determination of levocetirizine dihydrochloride and ambroxol hydrochloride in pharmaceutical dosage form. Spectrochim Acta A Mol Biomol Spectrosc. 2016 Jan 15;153:605-11. doi: 10.1016/j.saa.2015.09.014. Epub 2015 Sep 25. PubMed PMID: 26439526. 11: Hampel F, Ratner P, Haeusler JM. Safety and tolerability of levocetirizine dihydrochloride in infants and children with allergic rhinitis or chronic urticaria. Allergy Asthma Proc. 2010 Jul-Aug;31(4):290-5. doi: 10.2500/aap.2010.31.3349. PubMed PMID: 20819318. 12: Mahesh A, Shastri N, Sadanandam M. Development of taste masked fast disintegrating films of levocetirizine dihydrochloride for oral use. Curr Drug Deliv. 2010 Jan;7(1):21-7. PubMed PMID: 19863484. 13: Joshi S, Bhatia C, Bal CS, Rawat MS. Quantization of Dextromethorphan and Levocetirizine in Combined Dosage form Using a Novel Validated RP-HPLC Method. Indian J Pharm Sci. 2012 Jan;74(1):83-6. doi: 10.4103/0250-474X.102550. PubMed PMID: 23204629; PubMed Central PMCID: PMC3507352. 14: Sil A, Tripathi SK, Chaudhuri A, Das NK, Hazra A, Bagchi C, Islam CN. Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety. J Dermatolog Treat. 2013 Dec;24(6):466-72. doi: 10.3109/09546634.2012.750414. Epub 2013 Feb 3. PubMed PMID: 23163959. 15: Liu X, Du Y, Sun W, Kou J, Yu B. Study on the interaction of levocetirizine dihydrochloride with human serum albumin by molecular spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc. 2009 Dec;74(5):1189-96. doi: 10.1016/j.saa.2009.09.033. Epub 2009 Oct 4. PubMed PMID: 19857990. 16: Wichitnithad W, Jithavech P, Sanphanya K, Vicheantawatchai P, Rojsitthisak P. Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. J Chromatogr Sci. 2015 Nov-Dec;53(10):1663-72. doi: 10.1093/chromsci/bmv069. Epub 2015 Jun 17. PubMed PMID: 26084706. 17: Bachert C. A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther. 2009 May;31(5):921-44. doi: 10.1016/j.clinthera.2009.05.017. Review. PubMed PMID: 19539095. 18: Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004 Aug;18(4):399-411. Review. PubMed PMID: 15312146. 19: Schoepke N, Church MK, Maurer M. The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers. Acta Derm Venereol. 2013 May;93(3):286-93. doi: 10.2340/00015555-1490. PubMed PMID: 23147964. 20: Shawky NM, Shehatou GS, Abdel Rahim M, Suddek GM, Gameil NM. Levocetirizine ameliorates high fructose diet-induced insulin resistance, vascular dysfunction and hepatic steatosis in rats. Eur J Pharmacol. 2014 Oct 5;740:353-63. doi: 10.1016/j.ejphar.2014.07.021. Epub 2014 Jul 24. PubMed PMID: 25064340.

View History

NGJ9002

NGJ9002